that IPX066, this "new" extended-release carbi/levo formulation, was tested versus a placebo in one trial, and against immediate-release carbi/levo in an ongoing extension of the Phase III trials.

Not surprisingly, the results of the test versus placebo were a substantial (approx. 35%) improvement in the UPDRS parts II and III, reaching the targeted endpoints projected for the trial.

No results have been reported yet for the extension trial versus immediate release carbi/levo.

I wonder if this drug could reach the target endpoints if it were tested versus the already available controlled release formulations, either Merck's Sinemet CR or a generic.

One thing seems clear: If IPX066 is approved by the FDA, GSK and IMPAX will be marketing it at a major price increase over the available comparable drugs.

It is to be hoped that those of us who are successfully using existing controlled release formulations will still be able to obtain them